Fig. 4

Heart function was assessed in different groups by echocardiography. Data are mean ± SD. a-g M mode pictures in different treatment groups. a Control, b streptozotocin (STZ), c STZ + doxorubicin (STZ + DOX, d bone marrow-derived mesenchymal stem cells (BM-MSCs) before injection, e BM-MSCs post-treatment, f adipose tissue-derived mesenchymal stem cells (AT-MSCs) before injection, g AT-MSCs post-treatment, h percent fractional shortening (% FS), i LVESD, and j left ventricular end diastolic dimension (LVEDD). After 4 weeks of DOX treatment (8 weeks after STZ) heart function deteriorated; both BM-MSC and AT-MSC implantation improved heart function. *P <0.05 compared to respective baselines, ^@ P <0.05 compared to respective controls at time points, ^# P <0.05 compared to respective pretreatment (8 weeks), ^▲ P <0.05 compared to the untreated STZ + DOX group